For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 ...

BERLIN — A novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist combined into a single drug (LY3298176, Lilly), dubbed a "twincretin," ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — New recommendations from ACP on type 2 diabetes treatment include adding a GLP-1 agonist or SGLT-2 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. GLP-1 agonists and co-agonists conferred better ...

The findings of this cohort study suggest that glucagon-like peptide–1 receptor agonist (GLP-1 RA) use was associated with significant reduction in all-cause mortality among patients with cancer with ...

About The Study: Glucagon-like peptide receptor agonists (GLP-1RAs) were associated with lower risks of specific types of obesity-associated cancers compared with insulins or metformin in patients ...

A systematic review reveals that GLP-1 receptor agonists may help reduce certain substance use disorders, but findings are inconsistent due to study variability and patient differences. Review: ...

The cGAS-STING signaling pathway has emerged as a major focus in cancer immunotherapy because it stimulates interferon production and enhances antitumor immune responses. However, despite strong ...